Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.1% – Here’s Why

Capricor Therapeutics Inc (NASDAQ:CAPR) shares fell 6.1% during mid-day trading on Wednesday . The company traded as low as $13.95 and last traded at $14.16. 571,359 shares changed hands during mid-day trading, a decline of 26% from the average session volume of 774,542 shares. The stock had previously closed at $15.07.

Analyst Ratings Changes

Several research analysts have recently weighed in on CAPR shares. HC Wainwright reissued a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Piper Sandler started coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, Cantor Fitzgerald raised their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Stock Performance

The firm has a market capitalization of $650.58 million, a PE ratio of -13.50 and a beta of 4.08. The business’s 50 day moving average price is $14.53 and its 200-day moving average price is $12.43.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund boosted its stake in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 5,000 shares during the period. SG Americas Securities LLC purchased a new position in Capricor Therapeutics in the 3rd quarter valued at approximately $133,000. The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics in the third quarter worth $161,000. Sassicaia Capital Advisers LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter worth $192,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after acquiring an additional 15,872 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.